Scientific Advisory Board

Dr. Thomas Ichim, CEO, MediStem Inc. (OTCBB: MEDS).

Dr. Ichim had served as Chief of Scientific development for Medistem since January, 2007, before being promoted to his current role as CEO of the company. Prior to joining Medistem, he co-founded bioRASI, a translational contract research organization that performs clinical trials in multiple therapeutic areas, including stem cells, for clients ranging from small biotechs to large pharmaceutical companies. Dr. Ichim has held regulatory and executive positions in companies such as MarrowTech Pharma, Medvax, and ToleroTech Inc.  He has co-authored many scientific journal articles and is a peer reviewer for several scientific journals in the area of immunology and translational medicine. 

 

Dr. Vladimir Bogin, Senior VP, Cromos Pharma.

Dr. Bogin is Senior Vice-President and partner at Cromos Pharma, a contract research organization that specializes in biopharmaceutical clinical outsourcing to Russia and Eastern Europe. In addition, Dr. Bogin holds a Medical Faculty appointment at Pharmatech, a research management organization linking both Clinical Research Organization and Site Management Organization services to pharmaceutical and biotech clients for the development and management of clinical research trials, and he is a member of the Advisory Board at Stemcellpatents.com. Dr. Bogin has also held a Medical Faculty appointment at AdventRx Pharmaceuticals, and served as a Hospitalist in internal medicine at St. John Medical Center in Longview, WA, where he currently holds a Vice-Chairmanship in the Dept. of Medicine.
 

Dr. Ewa Carrier, Assoc. Professor of Clinical Medicine & Pediatrics, University of California at San Diego.

Dr. Carrier’s research focuses on stem cell biology and its transplantation to cancer and organ repair. Clinically, Dr. Carrier works on multiple protocols related to stem cell transplant for cancers, such as leukemias, lymphomas and multiple myeloma as well as autoimmune diseases. She participates in the protocols within the NIH-sponsored Clinical Trial Network, and is a member of a NIH-funded national consortium to treat autoimmune diseases with stem cells. Recently, two transplants on patients with lupus erythematosus (SLE) and myasthenia gravis,  both conditions in which the body’s immune system mistakenly attacks itself, were successfully performed at UCSD under Dr. Carrier. Dr. Carrier collaborates on clinical protocols using stem cells for cardiac repair and is involved in implementing protocols for stem cell transplants in type I diabetes. She has published numerous scientific articles and abstracts.
 

Dr. Linda Pilarski, Canada Research Chair in Biomedical Nanotechnology and Professor of Oncology, University of Alberta.

Dr. Pilarski is Team Leader for a CIHR (Canadian Institutes of Health Research) New Emerging Team to develop novel technology for genetic analysis of cancer, an initiative that links four institutions and two provinces in Western Canada and includes biomedical, clinical, engineering and sociology expertise and approaches. Research in the Pilarski lab focuses on understanding cancer, particularly of the immune system, as it occurs in cancer patients themselves, and on developing novel technology focused on better diagnosis and monitoring tools for the clinic. Dr. Pilarski also leads the  Alberta Cancer Diagnostics Consortium (ACDC), an initiative with Western Economic Diversification to develop microfluidic device prototypes for molecular diagnosis and monitoring as a “commercialization arm” of the CIHR New Emerging Team. She was an Eleanor Roosevelt International Cancer Research Fellow, an Associate Editor of the Journal of Immunology, and was Vice-President and then President of the Canadian Society of Immunology from 1993-1997. She was selected as YWCA Woman of Distinction for Science and Technology, and has been the recipient of McCalla and Killam Professorships at the University of Alberta. In 2002, she received the Cinader Award for research excellence and contributions to immunology, awarded by the Canadian Society for Immunology. Dr. Pilarski has published over 180 papers, and holds multiple patents, including several covering Orcrist's HYC750 technology for stem cell mobilization.
 

Dr. Eva Turley, Professor of Oncology, University of Western Ontario.

Dr. Turley is a world leader in the field of cell motility, hyaluronan receptors and their regulation of signaling pathways, focusing on the regulation of cell motility and tumor cell invasion. Over the years, her research collaborations with industry have been numerous. She has served as Vice-President of Research for Hyal Pharmaceutical Corporation, and co-founded Transition Therapeutics and Diagnostics. Furthermore, she has provided several pharmaceutical companies including Smith Kline Beecham, Cangene and Transition with novel ways of designing antibodies that are proving to be effective in regulating diseases as diverse as multiple sclerosis and cancer.

Dr. Turley has been active in numerous Boards and Panels including the National Research Council Advisory Council, NRC Executive, CISTI-NRC Committee, US Army Breast Cancer Panel, and the Heart and Stroke Foundation. She was the editor for "Women and Cancer" magazine, was a commentator on Genetic Research for "Quirks and Quarks" and "The National" for the CBC, and was the recipient of a YWCA Woman of Distinction Award.